Company news
Zhejiang Ausun Pharmaceutical Co., Ltd. Class A (SSE:603229) news
Zhejiang Ausun Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Aug 29, 2026: "Zhejiang Ausun Pharmaceutical Co., Ltd."Announcement on Provision…
Press releases & updates
"Zhejiang Ausun Pharmaceutical Co., Ltd."Announcement on Provision for Asset Impairment and Credit Impairment for the First Half of 2026
August 28, 2026
"Zhejiang Ausun Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
August 21, 2026
"Zhejiang Ausun Pharmaceutical Co., Ltd."Announcement on Implementation of Dividend Distribution for 2025
July 9, 2026
"Zhejiang Ausun Pharmaceutical Co., Ltd."Announcement on Overseas Marketing Authorization of the Cooperative Product
June 30, 2026
Announcement on Overseas Marketing Authorization of the Cooperative Product
June 25, 2026
Announcement on Obtaining Approval for Marketing of Chemical APIs
June 2, 2026
Announcement on Resignation of Secretary of the Board of Directors
May 21, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 20, 2026
Announcement on Listing of a Joint-stock Company on the Main Board of the Hong Kong Stock Exchange
May 13, 2026
Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital
April 28, 2026
Announcement on Returning the Raised Funds Used for Temporarily Supplementing Current Capital
April 24, 2026
Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Entecavir Tablets
March 20, 2026
Announcement on Early Returning of Some Raised Funds Temporarily Used for Supplementing Current Capital
February 25, 2026
Announcement on Company Re-certified as High-tech Enterprise
February 9, 2026
Announcement on Overseas Marketing Authorization of the Cooperative Product Tofacitinib Citrate Tablets
February 5, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
January 23, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
January 4, 2026
Announcement on Completing the Filing of the Articles of Association
December 10, 2025
奥翔药业关于选举职工代表董事的公告
November 18, 2025
Announcement on Postponing Some Investment Projects Financed by Raised Funds
October 30, 2025
Announcement on Obtaining of the "Drug Registration Certificate" for the Cooperative Product Imatinib Mesylate Tablets
September 16, 2025
Announcement on Resolutions of the 8th Meeting of the 4th Board of Directors
August 28, 2025
Announcement on Abnormal Fluctuations in Stock Trading
July 31, 2025
Announcement on Implementation of Dividend Distribution for 2024
July 9, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 20, 2025
Announcement on Using Idle Self-owned Funds for Cash Management
April 29, 2025
Announcement on Obtaining European CEP Certificate for Active Pharmaceutical Ingredient of Pilocarpine Hydrochloride
April 3, 2025
Announcement on Initially Repurchasing Shares through Call Auction and Progress in Shares Repurchase
March 5, 2025
Announcement on Obtaining Loan Commitment Letter for Share Repurchase from Financial Institutions
February 11, 2025
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Not Subject to Sales Restrictions Concerning Share Repurchase
February 5, 2025
Announcement on the Plan for Repurchasing Shares through Call Auction
January 26, 2025
Indicative Announcement on the Proposal from Controlling Shareholder, Actual Controller, and Chairman & General Manager to Repurchase Shares
January 14, 2025
Announcement on Obtaining Overseas Marketing Authorization for Cooperative Product Imatinib Mesylate Tablets
December 20, 2024
Announcement onUsing Some Idle Raised Funds to Temporarily Supplement Current Capital
December 13, 2024
Announcement on Returning the Raised Funds Used for Temporarily Supplementing the Working Capital
December 12, 2024
Announcement on Wholly-owned Subsidiary Obtaining "Drug Registration Certificate" for Sitafloxacin Tablets
December 5, 2024
Report for Q3 2024
October 29, 2024
Announcement on Convening Semi-annual Performance Briefing 2024
August 23, 2024